NewAmsterdam Pharma Company N.V.

XNASHealth care

Last traded price · USD

$20.93

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $20.93
Volume: —
Day's high: —
Day's low: —

In brief

NewAmsterdam Pharma Company N.V. is a health care company listed on Nasdaq, valued at about $2.50B.
Its shares closed at $20.93 on 4 Nov 2026, down 42.7% over the past year.
From India you can buy NAMS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy NewAmsterdam Pharma Company N.V. (NAMS) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole NAMS share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade NAMS options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −6.0% (SPY −1.6%, XLV +13.5%). 3 months: −23.7% (SPY −0.4%, XLV +15.5%). 1 year: −42.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NAMS, SPY and XLV · as of 4 Nov 2026
10.6 days to cover short interest
14.1M shares were sold short at the 15 Oct 2026 settlement, 11.8% of the 119.5M shares outstanding; covering them would take 10.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
9.4% above its 52-week low
Closed at $20.93 on 4 Nov 2026: 50.4% below the 52-week high of $42.21 (11 May 2026) and 9.4% above the low of $19.13 (23 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $20.93 was 6.7% below its 50-day average ($22.43) and 29.3% below its 200-day average ($29.62). It has closed below the 200-day for 82 sessions, since 13 Jul 2026. The 50-day average crossed below the 200-day on 15 Jun 2026, 99 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−6.0%

6 months−32.5%

1 year−42.7%

5 years—

Newswire

About

NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Website

Notable moves

December 10, 2024
+41.41%
January 10, 2024
+39.85%
December 15, 2022
+27.46%

NewAmsterdam Pharma Company N.V.

XNASHealth care

Last traded price · USD

$20.93

+0.00%Delayed · Pre-market

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 14:30 IST · A quote does not mean the product is available to trade on your account.

Day's open: —
Previous close: $20.93
Volume: —
Day's high: —
Day's low: —

In brief

NewAmsterdam Pharma Company N.V. is a health care company listed on Nasdaq, valued at about $2.50B.
Its shares closed at $20.93 on 4 Nov 2026, down 42.7% over the past year.
From India you can buy NAMS in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy NewAmsterdam Pharma Company N.V. (NAMS) shares from India?

Do I need the price of a whole NAMS share to invest?

How much can I invest in US stocks in a year?

Can I trade NAMS options or futures?

Insights

Quotes run fifteen minutes behind.

Behind SPY and its sector fund XLV over 1 year
1 month: −6.0% (SPY −1.6%, XLV +13.5%). 3 months: −23.7% (SPY −0.4%, XLV +15.5%). 1 year: −42.7% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: NAMS, SPY and XLV · as of 4 Nov 2026
10.6 days to cover short interest
14.1M shares were sold short at the 15 Oct 2026 settlement, 11.8% of the 119.5M shares outstanding; covering them would take 10.6 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
9.4% above its 52-week low
Closed at $20.93 on 4 Nov 2026: 50.4% below the 52-week high of $42.21 (11 May 2026) and 9.4% above the low of $19.13 (23 Oct 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026
Below its 50- and 200-day averages
The 4 Nov 2026 close of $20.93 was 6.7% below its 50-day average ($22.43) and 29.3% below its 200-day average ($29.62). It has closed below the 200-day for 82 sessions, since 13 Jul 2026. The 50-day average crossed below the 200-day on 15 Jun 2026, 99 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−6.0%

6 months−32.5%

1 year−42.7%

5 years—

Newswire

About

Website

Notable moves

December 10, 2024
+41.41%
January 10, 2024
+39.85%
December 15, 2022
+27.46%

NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. in brief

Behind SPY and its sector fund XLV over 1 year

10.6 days to cover short interest

9.4% above its 52-week low

Below its 50- and 200-day averages

NewAmsterdam Pharma Company N.V.

NewAmsterdam Pharma Company N.V. in brief

Behind SPY and its sector fund XLV over 1 year

10.6 days to cover short interest

9.4% above its 52-week low

Below its 50- and 200-day averages